Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 6
2017 6
2018 7
2019 8
2020 10
2021 9
2022 6
2023 16
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Dizman N, et al. Nat Med. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228755 Free PMC article. Clinical Trial.
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. El Zarif T, et al. Among authors: dizman n. J Clin Oncol. 2023 Jul 20;41(21):3712-3723. doi: 10.1200/JCO.22.02459. Epub 2023 May 16. J Clin Oncol. 2023. PMID: 37192435 Free PMC article.
Cancer Therapy Targeting CD47/SIRPα.
Dizman N, Buchbinder EI. Dizman N, et al. Cancers (Basel). 2021 Dec 11;13(24):6229. doi: 10.3390/cancers13246229. Cancers (Basel). 2021. PMID: 34944850 Free PMC article. Review.
Adjuvant treatment in renal cell carcinoma.
Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK. Dizman N, et al. Clin Adv Hematol Oncol. 2018 Aug;16(8):555-563. Clin Adv Hematol Oncol. 2018. PMID: 30148828 Review.
Genomic profiling in renal cell carcinoma.
Dizman N, Philip EJ, Pal SK. Dizman N, et al. Nat Rev Nephrol. 2020 Aug;16(8):435-451. doi: 10.1038/s41581-020-0301-x. Epub 2020 Jun 19. Nat Rev Nephrol. 2020. PMID: 32561872 Review.
Sequencing Therapies for Metastatic Renal Cell Carcinoma.
Dizman N, Arslan ZE, Feng M, Pal SK. Dizman N, et al. Urol Clin North Am. 2020 Aug;47(3):305-318. doi: 10.1016/j.ucl.2020.04.008. Epub 2020 Jun 11. Urol Clin North Am. 2020. PMID: 32600533 Review.
Therapeutic Sequencing in Metastatic Renal Cell Carcinoma.
Maia MC, Dizman N, Salgia M, Pal SK. Maia MC, et al. Among authors: dizman n. Kidney Cancer. 2017 Jul 26;1(1):15-29. doi: 10.3233/KCA-170006. Kidney Cancer. 2017. PMID: 30334001 Free PMC article. Review.
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, Frankel P, Llamas-Quitiquit M, Hsu J, Zengin ZB, Alcantara M, Castro D, Mercier B, Chawla N, Chehrazi-Raffle A, Barragan-Carrillo R, Jaime-Casas S, Govindarajan A, Gillece J, Trent J, Lee PP, Parks TP, Takahashi M, Hayashi A, Kortylewski M, Caporaso JG, Lee K, Tripathi A, Pal SK. Ebrahimi H, et al. Among authors: dizman n. Nat Med. 2024 Sep;30(9):2576-2585. doi: 10.1038/s41591-024-03086-4. Epub 2024 Jun 28. Nat Med. 2024. PMID: 38942995 Free PMC article. Clinical Trial.
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, Castro DV, Chan EH, Lee KO, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal SK. Dizman N, et al. Clin Genitourin Cancer. 2023 Oct;21(5):530-536. doi: 10.1016/j.clgc.2023.06.004. Epub 2023 Jun 25. Clin Genitourin Cancer. 2023. PMID: 37495481
65 results